Related Experiment Videos
[The first original Russian class-III antiarrhythmic nibentan]
Vestnik Rossiiskoi Akademii Meditsinskikh Nauk
|January 16, 1999
Summary
Nibentan, a new class-III antiarrhythmic drug, effectively treats atrial flutter, fibrillation, and supraventricular tachycardia. Its arrhythmogenic effects were inversely related to its antiarrhythmic action, and it is now approved for clinical use.
Area of Science:
- Cardiology
- Pharmacology
- Electrophysiology
Background:
- Atrial flutter, fibrillation, and supraventricular tachycardia are common arrhythmias.
- Existing antiarrhythmic drugs have limitations in efficacy and safety.
- Novel therapeutic agents are needed for effective arrhythmia management.
Purpose of the Study:
- To evaluate the experimental and clinical efficacy of the novel antiarrhythmic drug nibentan.
- To characterize the electrophysiological effects and ionic channel interactions of nibentan.
- To assess the safety profile and arrhythmogenic potential of nibentan.
Main Methods:
- Electrophysiological studies on cardiomyocytes to determine ionic channel effects.
- Clinical trials involving patients with various supraventricular and ventricular arrhythmias.
- Assessment of antiarrhythmic efficacy and incidence of arrhythmogenic effects.
Main Results:
- Nibentan acts as a class-III antiarrhythmic agent by inhibiting the delayed rectifier potassium current.
- High efficacy (70-100%) observed in patients with atrial flutter, fibrillation, and supraventricular tachycardia.
- Lower efficacy in suppressing ventricular premature contractions and tachycardia; arrhythmogenic effects inversely correlated with antiarrhythmic action.
Conclusions:
- Nibentan is a highly effective antiarrhythmic drug for supraventricular arrhythmias.
- The drug demonstrates a favorable safety profile with manageable arrhythmogenic effects.
- Nibentan has received approval for clinical use, offering a new treatment option for cardiac arrhythmias.